EGFR

Oncology·MeSH: Carcinoma, Non-Small-Cell Lung

47 drugs in development·26 companies·2 clinical trials

Drug Pipeline by Phase

Approved(11)

Drug	Company
Cyramza	ELI LILLY & Co (LLY)
Jardiance	ELI LILLY & Co (LLY)
Jardiance®	ELI LILLY & Co (LLY)
opdivo qvantig	BRISTOL MYERS SQUIBB CO (BMY)
pemetrexed	DR REDDYS LABORATORIES LTD (RDY)
pemfexy	EAGLE PHARMACEUTICALS, INC. (EGRX)
portrazza	ELI LILLY & Co (LLY)
rivfloza	Novo Nordisk A/S (NVO)
Tyvyt	ELI LILLY & Co (LLY)
Tyvyt®	ELI LILLY & Co (LLY)
vizimpro	PFIZER INC (PFE)

Phase 3(9)

Drug	Company
aumolertinib	EQRx, Inc. (EQRX)
erlotinib 150/100 mg	ASTRAZENECA PLC (AZN)
ivonescimab	Summit Therapeutics Inc. (SMMT)
Lazertinib	ENANTA PHARMACEUTICALS INC (ENTA)
olafertinib	Checkpoint Therapeutics, Inc. (CKPT)
Osimertinib	ENANTA PHARMACEUTICALS INC (ENTA)
Plinabulin	BeyondSpring Inc. (BYSI)
zipalertinib	Cullinan Therapeutics, Inc. (CGEM)
Zipalertinib (CLN-081/TAS6417)	Cullinan Therapeutics, Inc. (CGEM)

Phase 2(12)

Drug	Company
Amivantamab	ENANTA PHARMACEUTICALS INC (ENTA)
BDTX-1535	Black Diamond Therapeutics, Inc. (BDTX)
Chlorhexidine	Structure Therapeutics Inc. (GPCR)
Clindamycin	Structure Therapeutics Inc. (GPCR)
Clobetasol	Structure Therapeutics Inc. (GPCR)
Direct Oral Anticoagulant	Structure Therapeutics Inc. (GPCR)
Doxycycline	Structure Therapeutics Inc. (GPCR)
Minocycline	Structure Therapeutics Inc. (GPCR)
Pemetrexed	Structure Therapeutics Inc. (GPCR)
Timolol	Structure Therapeutics Inc. (GPCR)
wsd0922-fu	SUNSHINE BIOPHARMA INC. (SBFM)
Zinc gluconate	Structure Therapeutics Inc. (GPCR)

Phase 1(11)

Drug	Company
[111in]-fpi-2107	ASTRAZENECA PLC (AZN)
apg-1252	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
CX-904	CytomX Therapeutics, Inc. (CTMX)
E-SYNC T Cells	Filana Therapeutics Inc. (FLNA)
enozertinib	Oric Pharmaceuticals, Inc. (ORIC)
fpi-2053	ASTRAZENECA PLC (AZN)
ICP-189	ArriVent BioPharma, Inc. (AVBP)
nxp900	Nuvectis Pharma, Inc. (NVCT)
osimertinib	Nuvectis Pharma, Inc. (NVCT)
pf-8046052	LAVA Therapeutics NV (LVTX)
tno155 in combination with egf816	Novartis AG (NVS)

Preclinical(2)

Drug	Company
Fourth-Generation EGFR Inhibitor	Theseus Pharmaceuticals, Inc. (THRX)
THE-349	Theseus Pharmaceuticals, Inc. (THRX)

Phase 1/Phase 2(2)

Drug	Company
ATR-04	Azitra, Inc. (AZTR)
tno155	Novartis AG (NVS)

BioSniper tracks 47 drugs in development for EGFR across 26 companies.

There are 2 clinical trials targeting EGFR tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.